SPG82: A Protein Modulated By Small Molecules and A Drug Target

Target Name: PCYT2

NCBI ID: G5833

PCYT2

SPG82: A Protein Modulated By Small Molecules and A Drug Target

Post-Translational Modification (PTM) is a process by which proteins are modified after their synthesis, but before they become functional. These modifications can include adding or removing functional groups such as phosphate or acetyl groups, folding into specific shapes , or cleavage of the protein into smaller pieces. One of the most common PTMs is sialylation, which involves the addition of a sialic acid molecule to the cell surface of a protein. Sialic acid is a glycoprotein, which is a type of protein- carbohydrate complex that is covalently bound to a protein. Sialic acid is present on the cell surface of most tissues and is involved in many different cellular processes, including cell adhesion, signaling, and infection.

SPG82, also known as PCYT2 (Post-Translational Modification of Glycophorin A), is a protein that is produced by the liver and is found in most tissues of the body. SPG82 is a member of the glycophorin family, which includes proteins that are involved in the transport of various molecules across the cell membrane. The function of SPG82 is not well understood, but it is thought to play a role in the regulation of cellular processes such as inflammation, fibrosis, and autophagy.

SPG82 is a 21-kDa protein that is expressed in most tissues of the body. It is predominantly synthesized in the liver and is also found in the heart, kidneys, and lungs. SPG82 is a cytoplasmic protein, which means that it is primarily synthesized and exists within the cytoplasm of the cell. It is also a good example of a protein that is targeted by small molecules, which means that it can be modulated by small changes in the cellular environment.

Drug targeting

SPG82 is a drug target that can be modulated by small molecules. Many drugs that are used to treat various diseases are designed to modulate the activity of SPG82. For example, a drug called colesevelam is used to treat hypertension by modulating the activity of SPG82. Colesevelam is a peptide that consists of twoSPG82 molecules that are linked together. When colesevelam is administered to the body, it binds to a specific site on SPG82 and causes it to become less active. This can lead to a decrease in the production of cellular signaling molecules, which can cause a decrease in the blood pressure.

Another example of a drug that is designed to target SPG82 is a peptide called pegliride. Pegliride is also a peptide that consists of twoSPG82 molecules that are linked together. When pegliride is administered to the body, it binds to a specific site on SPG82 and causes it to become less active. This can lead to a decrease in the production of cellular signaling molecules, which can cause a decrease in the blood pressure.

Biomarker

SPG82 can also be used as a biomarker for certain diseases. For example, SPG82 can be used to monitor the effectiveness of a drug called colesevelam in treating hypertension. Since colesevelam is a peptide that consists of twoSPG82 molecules, a decrease in the activity of SPG82 can be used as a biomarker for the effectiveness of colesevelam.

Another example of a disease that can be monitored by SPG82 is fibrosis. Fibrosis is a disease in which cells become thickened and can no longer perform their normal functions. SPG82 can be used as a biomarker for

Protein Name: Phosphate Cytidylyltransferase 2, Ethanolamine

Functions: Ethanolamine-phosphate cytidylyltransferase that catalyzes the second step in the synthesis of phosphatidylethanolamine (PE) from ethanolamine via the CDP-ethanolamine pathway (PubMed:9083101, PubMed:31637422). Phosphatidylethanolamine is a dominant inner-leaflet phospholipid in cell membranes, where it plays a role in membrane function by structurally stabilizing membrane-anchored proteins, and participates in important cellular processes such as cell division, cell fusion, blood coagulation, and apoptosis (PubMed:9083101)

The "PCYT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCYT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets